Original title: Alpha-ketoglutarate alleviates chronic kidney disease via mitochondrial protection, gut microbiota, and metabolite remodeling
Juan Xie, Hailun Li, Haijing Dou, Yiyuan Zhang +6 · August 2026
Chronic kidney disease is a major worldwide health problem with no effective drug treatments. Researchers tested whether a nutritional supplement called alpha-ketoglutarate, or AKG, could help treat this condition in mice. They gave mice a special diet to cause kidney damage and treated them with AKG for 28 days. AKG works by protecting kidney cells and resetting internal biological systems. It repaired damage to mitochondria, which are the tiny powerhouses that make energy for cells. It also reshaped the gut microbiome, the community of bacteria living in the digestive system. By doing this, AKG altered key chemicals produced during metabolism. Overall, the researchers found that AKG reduced kidney damage, inflammation, and harmful tissue scarring in the mice. These results suggest that AKG protects kidneys through a combined defense: shielding cellular powerhouses, balancing gut bacteria, and fixing disrupted body chemicals.
Imagine your kitchen sink is clogged, and you try different cleaners without success. The real problem is not just the pipe but also the garbage disposal that grinds food waste, and the type of bacteria growing in the drain. Here, the kitchen sink is the kidney, the garbage disposal is the cell's energy factory, and the drain bacteria are the gut microbes. The supplement works like a combined cleaner that fixes the disposal, changes the bacteria, and clears the clog all at once.
Millions live with chronic kidney disease, often with no good drug options. This study suggests that alpha-ketoglutarate, a common supplement, might slow kidney damage by protecting cell powerhouses and rebalancing gut bacteria. That could mean a simple dietary addition for patients.
The study was performed in a mouse model, not humans. The mechanisms were predicted through bioinformatics and require experimental validation. The specific role of the FAK-PI3K/Akt axis was not directly tested. Long-term effects and safety in humans are unknown.
Ask anything about this paper. Answers come from its abstract, and say so when the abstract doesn't cover your question.
Alpha-ketoglutarate alleviates chronic kidney disease via mitochondrial protection, gut microbiota, and metabolite remodeling — Juan Xie, Hailun Li, Haijing Dou et al. — Journal of pharmaceutical and biomedical analysis — doi:10.1016/j.jpba.2026.117711
Abstract licence: CC BY
Explanation generated by Synthesis from the abstract — it is not the original paper.